RAND-2025: Adverse Events in Psychedelic Retreats

Study overview

RAND-2025 examines adverse event rates across psilocybin and ayahuasca participants in retreat and clinical settings. [CONTENT GAP: Study design, sample size, methodology, geographic scope, pending RAND-2025 PDF extraction and researcher review]

The analysis includes participants from [CONTENT GAP: population characteristics, clinical vs. retreat, demographics, medicine type breakdown, verify from RAND-2025]. Data collection and publication: 2025. [CONTENT GAP: DOI + publication details, confirm from RAND Corp website]

Key findings

Note: All statistics below are placeholders pending verified extraction from the RAND-2025 publication. No numbers go live without researcher and medical reviewer sign-off.

• [CONTENT GAP]

  Any adverse event (psilocybin + ayahuasca combined)

  Percentage of participants reporting any adverse event across retreat and clinical settings.

• [CONTENT GAP]

  Serious adverse events

  Hospitalization, lasting psychiatric harm, or death. Absolute numbers TBD from RAND-2025 methodology.

• [CONTENT GAP]

  Adverse events in rigorously screened populations

  Screening and preparation reduce serious adverse events, RAND-2025 identifies risk factors that align with Ceremonia's existing contraindications taxonomy.

• [CONTENT GAP]

  Participants in RAND-2025 analysis

  Study design, population, and timeframe, pending RAND-2025 methodology section extraction.

Adverse event categories and rates

RAND-2025 tracks the following adverse event categories: [CONTENT GAP: Specific categories and frequencies, anxiety, panic, fear, emotional distress, physical symptoms, suicidality, psychosis, medical emergency, extract from RAND-2025 Table X or appendix]

Risk factors for adverse events identified by RAND-2025 include: [CONTENT GAP: Risk factor list, pre-existing psychosis, uncontrolled bipolar, inadequate screening, inadequate preparation, poor set/setting, lack of integration, verify from RAND-2025 risk factor analysis section]

RAND-2025 in context: how it compares to prior research

Prior peer-reviewed literature from Imperial College London (Carhart-Harris et al.) and Johns Hopkins (Carbonaro et al., 2016; Griffiths et al.) established baseline adverse event profiles in clinical trial settings. RAND-2025 extends this to naturalistic retreat and non-clinical contexts where most participants actually engage.

Whether RAND-2025 affirms or extends prior findings in clinical populations: [CONTENT GAP: RAND-2025 vs. Imperial/Hopkins comparison, researcher to verify after RAND-2025 extraction; do not publish comparative claims without dual citation]

Limitations and caveats

No study is perfect. RAND-2025 limitations include known structural challenges in psychedelic adverse event research, plus study-specific constraints:

• —Self-report data: adverse events are participant-reported, not independently verified. Underreporting is possible in social retreat contexts.
• —Selection bias: retreat participants may differ systematically from clinical trial participants in motivation, resources, and baseline health status.
• —[CONTENT GAP: RAND-2025 specific methodological limitations, extract from methodology section before publish]
• —Publication bias: negative outcomes may be under-reported in self-selected retreat populations who are motivated to frame experiences positively.

RAND-2025 does not measure positive outcomes, depression remission, existential insight, lasting behavioral change. Future research is expected to quantify these. Adverse event counts also exclude challenging experiences (ego dissolution, temporary dissociation) that participants may report as net-positive in retrospect.

How Ceremonia applies these findings

RAND-2025 identifies the same risk factors our screening process was already built to catch. That alignment matters, it means our contraindications taxonomy is not arbitrary. It reflects what the evidence says increases risk.

• →

  Rigorous screening

  Pre-existing psychosis, uncontrolled bipolar, and absence of medical review are identified as risk factors in RAND-2025. These are Tier 1 absolute contraindications in our screening framework. We do not waive them.

• →

  Preparation and education

  RAND-2025 identifies inadequate preparation as a risk factor. Every participant goes through pre-retreat coaching covering intention, fear, and the full range of possible experience, including difficult territory.

• →

  Trained facilitation

  Presence of experienced facilitators correlates with lower serious adverse event rates in retreat contexts. Our facilitator team trains together and has a defined emergency protocol, not ad hoc improvisation.

• →

  Integration support

  Post-retreat integration reduces lasting harm. Integration calls are included in retreat cost, not sold separately as an upsell. RAND-2025 confirms this is not optional.

Absolute risks in context

Percentages alone are hard to evaluate without a comparison. [CONTENT GAP: “X% serious events = 1 in Y people” phrasing, attorney review required for liability before publish; compare to psychiatric medication adverse event baselines]

Context matters. The relevant comparison is not “risk vs. no risk” but “risk of psychedelic-assisted work vs. risk of untreated depression, untreated PTSD, or long-term psychotropic medication.” RAND-2025 does not make this comparison directly, but the broader literature does.

References

• RAND Corporation. (2025). [CONTENT GAP: Full citation, title, authors, DOI, journal or report series, verify from RAND Corp website or HAGT webinar transcript].
• Carbonaro, T. M., et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring consequences. Journal of Psychopharmacology, 30(12), 1268–1278.
• Carhart-Harris, R. L., et al. Imperial College London psilocybin clinical trial safety profiles (multiple publications 2016–2022). Full bibliography at /science/research-library.